we keep life real and safe by providing botanical-dna based security and authentication solutions and services that protect assets, products, brands, supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.
Company profile
Ticker
APDN, APPDW
Exchange
Website
CEO
James Hayward
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
PROHEALTH MEDICAL TECHNOLOGIES INC, DCC ACQUISITION CORP, DATALINK CAPITAL CORP/TX/
SEC CIK
Corporate docs
Subsidiaries
APDN (B.V.I.) Inc. • Applied DNA Sciences Europe Limited • Applied DNA Sciences India Private Limited • LineaRX, Inc. • Applied DNA Clinical Labs LLC • Spindle Biotech, Inc. ...
IRS number
592262718
APDN stock data
Latest filings (excl ownership)
S-1
IPO registration
23 Apr 24
8-K/A
Amendments to Articles of Incorporation or Bylaws
23 Apr 24
8-K
Applied DNA Announces 1-For-20 Reverse Stock Split
22 Apr 24
8-K
Entry into a Material Definitive Agreement
19 Apr 24
8-K
Submission of Matters to a Vote of Security Holders
16 Apr 24
EFFECT
Notice of effectiveness
21 Mar 24
424B3
Prospectus supplement
20 Mar 24
S-1/A
IPO registration (amended)
15 Mar 24
DEFA14A
Additional proxy soliciting materials
14 Mar 24
DEF 14A
Definitive proxy
14 Mar 24
Transcripts
APDN
Earnings call transcript
2024 Q1
8 Feb 24
APDN
Earnings call transcript
2023 Q4
7 Dec 23
APDN
Earnings call transcript
2023 Q3
10 Aug 23
APDN
Earnings call transcript
2023 Q2
12 May 23
APDN
Earnings call transcript
2023 Q1
9 Feb 23
APDN
Earnings call transcript
2022 Q4
17 Dec 22
APDN
Earnings call transcript
2022 Q3
11 Aug 22
APDN
Earnings call transcript
2022 Q2
14 May 22
APDN
Earnings call transcript
2022 Q1
10 Feb 22
APDN
Earnings call transcript
2021 Q4
10 Dec 21
Latest ownership filings
SC 13G
Grossman Bruce
12 Feb 24
SC 13G/A
AWM Investment Company, Inc.
10 Jan 24
4
Beth Jantzen
27 Mar 23
4
Clay Shorrock
27 Mar 23
4
Judith Murrah
27 Mar 23
SC 13G
AWM Investment Company, Inc.
14 Feb 23
SC 13G/A
Grossman Bruce
9 Feb 23
4
YACOV A SHAMASH
27 Jan 23
4
Scott L Anchin
27 Jan 23
4
Joseph D. Ceccoli
27 Jan 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 23 | Sep 22 | Sep 21 | Sep 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 7.90 mm | 7.90 mm | 7.90 mm | 7.90 mm | 7.90 mm | 7.90 mm |
Cash burn (monthly) | 1.20 mm | 609.46 k | 1.39 mm | 1.15 mm | 893.26 k | 518.14 k |
Cash used (since last report) | 8.28 mm | 4.20 mm | 9.58 mm | 7.94 mm | 6.15 mm | 3.57 mm |
Cash remaining | -376.69 k | 3.70 mm | -1.68 mm | -41.11 k | 1.75 mm | 4.33 mm |
Runway (months of cash) | -0.3 | 6.1 | -1.2 | -0.0 | 2.0 | 8.4 |
Institutional ownership, Q3 2023
16.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 31 |
Opened positions | 5 |
Closed positions | 3 |
Increased positions | 6 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 3.20 bn |
Total shares | 2.79 mm |
Total puts | 9.10 k |
Total calls | 91.80 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
AWM Investment | 808.81 k | $994.83 mm |
AMH Equity | 587.23 k | $710.55 mm |
Vanguard | 523.69 k | $633.67 mm |
Susquehanna International | 140.19 k | $172.44 mm |
Hirschman Orin | 140.00 k | $620.00 k |
Geode Capital Management | 139.19 k | $171.26 mm |
BLK Blackrock | 101.66 k | $123.01 mm |
Atria Wealth Solutions | 81.01 k | $98.02 mm |
STT State Street | 75.68 k | $93.08 mm |
Raymond James & Associates | 49.88 k | $60.35 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 Mar 23 | Jantzen Beth | Common Stock | Grant | Acquire A | No | No | 0 | 91,667 | 0.00 | 91,739 |
23 Mar 23 | Jantzen Beth | NQSO Common Stock | Grant | Acquire A | No | No | 1.08 | 1,961 | 2.12 k | 1,961 |
23 Mar 23 | Jantzen Beth | Incentive Stock Option Common Stock | Grant | Acquire A | No | No | 1.08 | 98,039 | 105.88 k | 98,039 |
23 Mar 23 | Clay Shorrock | Common Stock | Grant | Acquire A | No | No | 0 | 91,667 | 0.00 | 91,667 |
23 Mar 23 | Clay Shorrock | NQSO Common Stock | Grant | Acquire A | No | No | 1.08 | 1,961 | 2.12 k | 1,961 |
23 Mar 23 | Clay Shorrock | Incentive Stock Option Common Stock | Grant | Acquire A | No | No | 1.08 | 98,039 | 105.88 k | 98,039 |
23 Mar 23 | Murrah Judith | Common Stock | Grant | Acquire A | No | No | 0 | 99,306 | 0.00 | 101,853 |
23 Mar 23 | Murrah Judith | NQSO Common Stock | Grant | Acquire A | No | No | 1.08 | 10,294 | 11.12 k | 10,294 |
23 Mar 23 | Murrah Judith | Incentive Stock Option Common Stock | Grant | Acquire A | No | No | 1.08 | 98,039 | 105.88 k | 98,039 |
25 Jan 23 | Catell Robert B | NQSO Common Stock | Grant | Acquire A | No | No | 1.41 | 39,428 | 55.59 k | 39,428 |
News
Why Teledyne Technologies Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
24 Apr 24
Applied DNA Announces 1-For-20 Reverse Stock Split, Will Begin Trading On A Split-Adjusted Basis Commencing Upon Market Open On Thursday, April 25, 2024
22 Apr 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
20 Mar 24
HC Wainwright & Co. Maintains Buy on Applied DNA Sciences, Adjusts Price Target To $1.5
9 Feb 24
Recap: Applied DNA Sciences Q1 Earnings
8 Feb 24
Press releases
Applied DNA Awarded Contract by HDT Bio For Rapid Vaccine Development Program
25 Apr 24
Applied DNA Announces 1-For-20 Reverse Stock Split
22 Apr 24
Applied DNA to Showcase Linea(TM) DNA and Linea(TM) IVT Platforms at 24th Annual World Vaccine Congress
14 Mar 24
Applied DNA Announces First Quarter Fiscal Year 2024 Financial Results
8 Feb 24
Applied DNA to Report First Quarter Fiscal 2024 Financial Results on Thursday, February 8, 2024
5 Feb 24